New York, USA – April 27, 2022 – CD BioGlcyo, a biotechnology company that offers a full range of glycobiology-related products, analysis, custom synthesis and design to advance glycobiology research, recently announced the release of a variety of technology platforms to advance quantitative analysis of glycoproteins.
Glycoproteomics quantitative analysis refers to the quantitative analysis of glycosylated proteins from the omics level. Glycosylated proteins, or glycoproteins, refer to proteins that contain oligosaccharide chains (glycans) covalently bound to amino acid side chains. More than 50% of proteins in cells are glycosylated, but the vast majority of glycoproteins have not yet been discovered. Glycosylation modification not only affects the spatial conformation, biological activity, transportation and localization of proteins, but also plays a crucial role in various biological processes such as molecular recognition, cellular communication, immune response, and cell differentiation, so it is of great significance to study glycoproteomics. Quantitative analysis of glycoproteins is one of the research contents of glycoproteomics, which helps to find the expression differences of glycoproteins in different physiological or pathological states of organisms, thus providing ideas and insights for research.
Now, CD BioGlyco provides a variety of glycoprotein quantitative analysis technology platforms, mainly including fluorescence spectroscopy, capillary electrophoresis, laser-induced fluorescence detection, fluorophore hydrophilic interaction chromatography, and mass spectrometry.
Quantitative analysis of glycoproteins at CD BioGlyco mainly includes:
Relative quantification of glycoproteins through strategies that combine isotope labeling/isotope-free labeling with a variety of advanced mass spectrometry techniques.
Several absolute quantification methods based on the characteristics of glycoproteins to provide technical support.
“In the past months, the life sciences industry has moved forward in an unprecedented way. We are honored to have played an important role in the effort. The cutting-edge facilities and technologies we’re unveiling today will further support innovation across glycoproteomics. Our multi-platform approach and well-trained researchers will greatly accelerate our clients’ research and help them explore glycobiology more comprehensively and accurately.” Commented Anna, one of the representative speakers from CD BioGlyco.
For more details on CD BioGlyco’s glycoprotein quantification service, please visit https://www.bioglyco.com/glycoprotein-quantification.html.